logo-loader
viewVolitionRx

VolitionRx gets $500,000 loan to continue build-up of veterinary medicine subsidiary

Volition’s Nu.Q platform looks for molecular signatures of cancer by detecting nucleosomes, a process that also works in dogs

Cameron Reynolds and Brett Cornwell shaking hands
On October 25, Volition signed multiple agreements with Texas A&M University to help develop its Nu.Q Vet products

VolitionRx Limited (NYSEAMERICAN:VNRX) has received a $500,000 loan to further the development of its Volition Veterinary Diagnostics Development LLC subsidiary. 

Specifically, the new infusion of non-dilutive funding comes from SOFINEX, a funding agency of the Walloon Region, where Volition is based.

READ: VolitionRx's veterinary subsidiary wins 12.5% equity stake from Texas A&M

"We are delighted with the non-dilutive financial support we continue to receive as it allows us to develop Nu.Q Vet products in the very exciting veterinary market,” Gaetan Michel, CEO of Belgian Volition. “We would like to thank SOFINEX for this latest loan which takes our non-dilutive funding total from local agencies and the Walloon government to over $6 million to-date."

On October 25, Volition signed multiple agreements with Texas A&M University to help develop its Nu.Q Vet products, and the institution now holds a 12.5% stake in the company. The two parties recently attended a signing ceremony at the school's College of Veterinary Medicine & Biomedical Sciences.

Volition’s Nu.Q platform looks for molecular signatures of cancer by focusing on the nucleosomes – a section of DNA wrapped around a core of proteins – in the blood. As cancer cells multiply, they are modified in a way that distinguishes them from healthy cells and the traits of the malignant disease appear on the nucleosomes, which are analyzed by the platform.

The company and the university together have been studying a version of its blood-based tests for animals called Nu.Q Vet after discovering that nucleosomes in the blood can also be detected in dogs.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: VolitionRx

Price: 4.58 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $188.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

1 week, 1 day ago

2 min read